Background and Objectives. The biological characteristics and prognostic significance of the internal tandem duplication of the FLT3 (FLT3/ITD) were investigated in a series of de novo acute myeloid leukemia (AML) patients. One hundred and fifty-six adult patients with AML were included in the study. FLT3/ITD was detected in 41 (26%) patients (FLT3/ITD+). Design and Methods. The main differences observed between the groups with and without FLT3/ITD: a higher leukocyte count, a raised percentage of a normal karyotype and a more frequent M5 FAB diagnosis in the FLT3/ITD+ patients. As regards the immunophenotypic characteristics the FLT3/ITD+ group very often expressed monocytic markers (CD36 and CD11b) and less commonly immature markers (CD34 and CD117). A promyelocytic-like immunophenotype pattern was also detected in a minority of these patients (4/36). Results. The FLT3/ITD+ patients had a shorter overall survival. a shorter event-free survival and a higher probability of relapse. Minimal residual disease (MRD) was investigated in the FLT3/ITD+ patients using flow cytometry. This technique had a sensitivity of 62% and a specificity of 83% in relapse prediction. Minimal residual disease analysis was hampered by the low number of patients with detectable aberrant immunophenotype. Interpretation and Conclusions. A high frequency of changes in the phenotype and/or genotype pattern between diagnosis and relapse was detected (5/6). FLT3/ITD is a frequent molecular lesion in de novo adult AML and seems to be associated with momnocytic differentaition, a high leukocyte count and a poor prognosis. Immunophenotype and genotype patterns observed at relapse suggest that the FLT3/ITD+ blasts may be genetically unstable and prone to clonal evolution. FLT3/ITD may not be a suitable target for minimal residual disease studies. (C) 2003, Ferrata Storti Foundation.
机构:
Chaim Sheba Med Ctr, Tel Hashomer, IsraelJohns Hopkins Univ, Baltimore, MD USA
Nagler, Arnon
Wei, Andrew H.
论文数: 0引用数: 0
h-index: 0
机构:
Royal Melbourne Hosp, Walterand Eliza Hill Inst Med Res, Peter MacCallum Canc Ctr, Melbourne, Australia
Univ Melbourne, Melbourne, AustraliaJohns Hopkins Univ, Baltimore, MD USA
Wei, Andrew H.
Marcucci, Guido
论文数: 0引用数: 0
h-index: 0
机构:
Beckman Res Inst City Hope, Duarte, CA USAJohns Hopkins Univ, Baltimore, MD USA
Marcucci, Guido
Geller, Nancy L.
论文数: 0引用数: 0
h-index: 0
机构:
NHLBI, Bethesda, MD USAJohns Hopkins Univ, Baltimore, MD USA
Geller, Nancy L.
Hasabou, Nahla
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
Hasabou, Nahla
Delgado, David
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
Delgado, David
Rosales, Matt
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
Rosales, Matt
Hill, Jason
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
Hill, Jason
Gill, Stanley C.
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
Gill, Stanley C.
Nuthethi, Rishita
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Northbrook, IL USAJohns Hopkins Univ, Baltimore, MD USA
机构:
Columbia Univ, Irvine Med Ctr, NewYork Presbyterian Hosp, Hematol Oncol, New York, NY USAColumbia Univ, Irvine Med Ctr, NewYork Presbyterian Hosp, Hematol Oncol, New York, NY USA
Thomas, Christan M.
Campbell, Peter
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, Irvine Med Ctr, NewYork Presbyterian Hosp, Hematol Oncol, New York, NY USAColumbia Univ, Irvine Med Ctr, NewYork Presbyterian Hosp, Hematol Oncol, New York, NY USA